About Dr. Rabin

Dr. Dave Rabin, MD, PhD, is a neuroscientist, board-certified psychiatrist, health tech entrepreneur & inventor who has been studying the impact of chronic stress in humans for over 15 years. He is the co-founder & Chief Medical Officer at Apollo Neuroscience, which has developed the first scientifically-validated wearable technology that actively improves sleep, relaxation, focus, and calm, using a novel touch therapy that signals safety to the brain. Dr. Rabin is the Executive Director of The Board of Medicine & the Medical Director of the Apollo Clinic.

 

Dr. Rabin has appeared in

david-rabin-vouge.png
david-rabin-mens-health.png
Dr Dave CV

Committed to supporting the healing process

Dr. Rabin has always been fascinated by consciousness and our inherent ability to heal ourselves from injury and illness. His research focuses on the clinical translation of non-invasive therapies for patients with treatment-resistant illnesses like PTSD and substance use disorders.

In addition to his clinical psychiatry practice, Dr. Rabin is currently conducting research on the epigenetic regulation of trauma responses and recovery to elucidate the mechanism of psychedelic-assisted psychotherapy and the neurobiology of belief.

Dr. Rabin received his MD in medicine and PhD in neuroscience from Albany Medical College and specialized in psychiatry with a distinction in research at Western Psychiatric Institute & Clinic at the University of Pittsburgh Medical Center.

Supporting harm-reduction, safety, education, and innovation in medicine and public health

Dr. Rabin is also the executive director of The Board of Medicine, a 501(c)(3) nonprofit organization of world-renowned physicians and scientists establishing evidence-based clinical guidelines for the production and safe use of currently unregulated alternative medicines, including plant medicines. The Board of Medicine trains and certifies healthcare providers and provides quality control standards for complementary and alternative medicines to support high-quality clinical research, best practices, and risk-reduction.